Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been newly diagnosed with pancreatic cancer (a specific type called adenocarcinoma), confirmed by a biopsy.
• The cancer must be considered removable by surgery, as assessed by the study team.
• People who agree to have a tumor biopsy as part of the study.
• People who are generally well enough to carry out daily activities with little to no limitation (as measured by a standard health performance scale called ECOG, scored 0 or 1).
• People whose heart, liver, kidneys, and other organs are functioning well enough, based on blood and other lab tests specified by the study.
• Women who could become pregnant must have a negative blood pregnancy test before joining.
• Both men and women must agree to use an approved form of contraception for the duration of the study.

Who may not be able to join:

• People who have already received any treatment specifically targeting pancreatic cancer, or any prior cancer immunotherapy (treatments for symptoms only may be allowed — confirm with trial site).
• People who have been diagnosed with another cancer that could affect the safety or results of this study.
• People with serious uncontrolled health conditions, such as an uncontrolled infection, heart failure, unstable chest pain, irregular heartbeat, cancer that has spread to other parts of the body, or mental health or personal circumstances that would make it hard to follow the study requirements.
• People with an active autoimmune disease (a condition where the immune system attacks the body's own tissues).
• People who have taken high-dose steroid medications or immune-suppressing drugs within 14 days before the first study treatment (confirm with trial site for exact dose thresholds).
• People with an active infection that requires treatment with medications that work throughout the whole body.
• People with a known history of HIV.
• People with active or ongoing hepatitis B or hepatitis C infection.
• People with known active tuberculosis.
• People with a history of certain lung conditions, including scarring of the lung tissue, acute lung disease, chronic obstructive pulmonary disease (COPD), or asthma requiring medication.
• People who have previously had a stem cell transplant or an organ transplant from another person.
• People who have had a major surgery requiring general anaesthesia within 28 days before the first study treatment.
• People who have received a live vaccine within 28 days before the first study treatment.
• People with a history of a severe allergic reaction to any monoclonal antibody medication (a type of targeted therapy).
• People who are currently participating in another clinical trial involving a treatment.
• People who are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.